{"id":90774,"date":"2023-12-01T14:39:57","date_gmt":"2023-12-01T09:09:57","guid":{"rendered":"http:\/\/finservwealth.com\/zydus-life-gains-on-usfda-nod-for-heart-drug\/"},"modified":"2023-12-01T14:39:57","modified_gmt":"2023-12-01T09:09:57","slug":"zydus-life-gains-on-usfda-nod-for-heart-drug","status":"publish","type":"post","link":"https:\/\/finservwealth.com\/hi\/zydus-life-gains-on-usfda-nod-for-heart-drug\/","title":{"rendered":"Zydus Life gains on USFDA nod for heart drug"},"content":{"rendered":"<p> Zydus Lifesciences may be eligible for 180 days of shared generic exclusivity for Ivabradine tablets which reduce the risk of hospitalisation for worsening heart failure in adult patients<\/p><div id=\"finse-3667117600\" class=\"finse-content finse-entity-placement\"><script async src=\"\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-9118214110898834\" crossorigin=\"anonymous\"><\/script><ins class=\"adsbygoogle\" style=\"display:block;\" data-ad-client=\"ca-pub-9118214110898834\" \ndata-ad-slot=\"\" \ndata-ad-format=\"auto\"><\/ins>\n<script> \n(adsbygoogle = window.adsbygoogle || []).push({}); \n<\/script>\n<\/div>\n<p><a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/zydus-life-gainsusfda-nod-for-heart-drug_17356681.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a><\/p>\n<p>\u200b\u00a0Zydus Lifesciences may be eligible for 180 days of shared generic exclusivity for Ivabradine tablets which reduce the risk of hospitalisation for worsening heart failure in adult patients Zydus Lifesciences may be eligible for 180 days of shared generic exclusivity for Ivabradine tablets which reduce the risk of hospitalisation for worsening heart failure in adult patients\u00a0\u00a0Moneycontrol Latest News\u00a0<a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/zydus-life-gainsusfda-nod-for-heart-drug_17356681.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a>\u00a0\u00a0<\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<p> Zydus Lifesciences may be eligible for 180 days of shared generic exclusivity for Ivabradine tablets which reduce the risk of hospitalisation for worsening heart failure in adult patients<\/p>\n<p><a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/zydus-life-gainsusfda-nod-for-heart-drug_17356681.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a><\/p>\n<p>\u200b\u00a0Zydus Lifesciences may be eligible for 180 days of shared generic exclusivity for Ivabradine tablets which reduce the risk of hospitalisation for worsening heart failure in adult patients Zydus Lifesciences may be eligible for 180 days of shared generic exclusivity for Ivabradine tablets which reduce the risk of hospitalisation for worsening heart failure in adult patients\u00a0\u00a0Moneycontrol Latest News\u00a0<a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/zydus-life-gainsusfda-nod-for-heart-drug_17356681.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a>\u00a0\u00a0<\/p>\n<p><!-- \/wp:html --> Zydus Lifesciences may be eligible for 180 days of shared generic exclusivity for Ivabradine tablets which reduce the risk of hospitalisation for worsening heart failure in adult patients<\/p>","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"content-type":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"","neve_meta_content_width":0,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","_themeisle_gutenberg_block_has_review":false,"footnotes":""},"categories":[70],"tags":[],"class_list":["post-90774","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-latest-news"],"jetpack_featured_media_url":"https:\/\/www.moneycontrol.com\/news_image_files\/2022\/200x200\/Z\/Zydus-7_200.jpg","_links":{"self":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts\/90774","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/comments?post=90774"}],"version-history":[{"count":0,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts\/90774\/revisions"}],"wp:attachment":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/media?parent=90774"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/categories?post=90774"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/tags?post=90774"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}